To the Editor: Obstructive sleep apnea (OSA) is consistently associated with increased risk for cardiovascular (CV) disease (1), but the large-scale, international SAVE (Sleep Apnea and Cardiovascular Endpoints) randomized trial showed that continuous positive airway pressure (CPAP) treatment did not prevent serious CV events in high-risk patients (2). One explanation is that SAVE showed a nonsignificant, <1.0 mm Hg systolic blood pressure (BP) difference between CPAP-treated and usual care (UC) groups over a mean follow-up of 3.7 years, which was smaller than expected based on short-term trials (3). To provide greater insight into the SAVE results, we wish to report further data on mean BP and visit-to-visit BP variability (BPV) across the first 24 months of the study. Although increasing evidence supports an association of BPV and CV events (4), the importance of this key BP parameter in relation to CPAP treatment for OSA is uncertain (5, 6). Some of these results have been presented in abstract form (7, 8).
|Number of pages||3|
|Journal||American journal of respiratory and critical care medicine|
|Publication status||Published - 1 Jan 2019|
- Cardiovascular disease
- Sleep apnea
- blood pressure